Influenza Other Respir Viruses January 2023 PMID 36369772

Respiratory syncytial virus disease burden in adults aged 60 years and older in high-income countries: A systematic literature review and meta-analysis.

Miloje Savic, Yolanda Penders, Ting Shi, Angela Branche, Jean-Yves Pirçon

Full text PDF Download social card

Mentions

Peak: 15 in Nov 2022

across 4 sources since Nov 2022

Extended reach

1,117,988

potential audience

Total likes

2,061

Video views

1,040,286

Mentions per month

Nov 2022 – May 2025

Where it's discussed

News53 articles
X / Twitter23 posts
YouTube4 videos
Blogs2 articles

AI synopsis

What people are saying

The consensus among digital discussions emphasizes the significant burden of RSV in older adults and the importance of preventative measures, supported by data such as '470,000 hospitalizations' and references to new vaccines like GSK’s Arexvy. The tone is factual and forward-looking, reflecting both concern and optimism about addressing this overlooked health issue.

AgreementModerate agreement

Most discussions acknowledge the importance of the study, recognizing RSV as a significant health issue in older adults, with phrases like 'underscores the need for preventative measures' indicating support.

InterestHigh interest

The discussions show high interest, especially through mentions of vaccine developments and disease burden statistics, which engage the audience with relevant data and ongoing concerns.

EngagementModerate engagement

Participants engage by referencing specific data points, such as '5.2 million cases' and '33,000 deaths,' and sharing implications for public health strategies, indicating a moderate level of deep involvement.

ImpactModerate impact

The discussions highlight the potential influence of the research on policy and health interventions, emphasizing the need for vaccines and treatment options, suggesting it can drive real-world change.

Abstract in brief

The study reviews how common and serious respiratory syncytial virus (RSV) is among adults aged 60 and older in wealthy countries, finding that RSV causes more illness and death in this group than previously thought.
It analyzed 21 studies from various high-income countries, concluding that in 2019 there were roughly 52 million cases, 470,000 hospitalizations, and 33,000 in-hospital deaths due to RSV in adults over 60.
The findings suggest that RSV significantly impacts older adults in these countries, emphasizing the need for preventative measures like vaccines or treatments to protect this vulnerable age group.

Read the full abstract

All mentions

RSV Impact on Older Adults in High-Income Countries

This study reviews how common and serious respiratory syncytial virus (RSV) is among adults aged 60 and older in wealthy countries, highlighting its significant health burden and the importance of preventative measures…

Mommy Doc Ph · Apr 19, 2025 590,075 views

RSV in Older Adults: Risks and Lack of Treatments

RSV can cause severe complications in adults 60 and up, including hospitalization and death. Currently, there are no specific treatments for RSV. Learn about its impact on older adults and the importance of preventive…

Mommy Doc Ph · May 2, 2025 450,104 views

RSV Impact and Burden in Adults Over 60 in High-Income Countries

The study reviews how common and serious respiratory syncytial virus (RSV) is among adults aged 60 and older in wealthy countries, finding that RSV causes more illness and death in this group than previously thought. It…

Mommy Doc Ph · May 23, 2025 74 views

Understanding the Impact of RSV on Older Adults and Lack of Treatment Options

RSV causes significant illness and death among adults 60 and older, with millions affected annually. No specific treatment exists, highlighting the importance of prevention and vaccination for this vulnerable population.

Mommy Doc Ph · May 30, 2025 35 views

まねきねこ(薬害＆医療ミス被害、ME/CFS,PS8、パワハラ被害者)

@NA19H5hHBdTdrDr · X

RT @keisuke4713: 2024/5/31発売　＊昨日,医師向けCM:1年後の安全性 RSウイルス

May 16, 2025 · 3 shares · 1,386 followers View post →

studio菊正

@studio_kikumasa · X

RT @keisuke4713: 2024/5/31発売　＊昨日,医師向けCM:1年後の安全性 RSウイルス

May 2, 2025 · 3 shares · 117 followers View post →

Tabatha

@araran100 · X

RT @keisuke4713: 2024/5/31発売　＊昨日,医師向けCM:1年後の安全性 RSウイルス

Apr 28, 2025 · 3 shares · 17,533 followers View post →

tune

@keisuke4713 · X

2024/5/31発売　＊昨日,医師向けCM:1年後の安全性 RSウイルス

Apr 28, 2025 · 4 likes · 3 shares · 3,731 followers View post →

I love you darling⚢

@lesbiennedetoi · X

RT @mimiryudo: Concernant le VRS, le principal du fardeau concerne : - nourrissons < 2 ans - personnes âgées, comorbidités (https://t.co/L…

Oct 4, 2023 · 1 share · 1,178 followers View post →

Ecole et Familles Oubliées

@Ecole_Oubliee · X

RT @mimiryudo: Concernant le VRS, le principal du fardeau concerne : - nourrissons < 2 ans - personnes âgées, comorbidités (https://t.co/L…

Oct 4, 2023 · 1 share · 5,504 followers View post →

Michaël

@mimiryudo · X

Oct 4, 2023 · 3 likes · 1 share · 17,447 followers View post →

PositiveLiving

@TheAsthmaCures · X

GSK's Arexvy, the first respiratory syncytial virus (RSV) vaccine for older adults ... - Medindia https://t.co/g4jii1iit7 Respiratory syncytial virus disease burden in adults aged 60 years and older in high-income countries: a systematic literature review and ...

Aug 5, 2023 · 179 followers View post →

PROMISE Project

@PROMISE_IMI · X